AACF - Antiviral Testing in Animals Program

AACF Antiviral Testing in Animals Program

Program Purpose:

This purpose of this resource is to help investigators who need help in generating efficacy data for their proposed antiviral candidate or immunomodulator in the following animal models of human viral diseases.

NIAID Project Officer in charge of AACF Antiviral Testing in Animals -

Heather L. Greenstone, PhD
Program Officer, Virology Branch
Division of Microbiology and Infectious Diseases, NIAID, NIH
Room 4089
6610 Rockledge Drive, MSC 6603
Bethesda, MD 20892-6603

Phone: 301-496-7453
FAX: 301-480-1594
e-mail: hgreenstone@niaid.nih.gov

List of Assays:

Protocol for Requesting Access to AACF Antiviral Testing in Animals

Before any compounds are considered for this service, all submitters must sign the NIAID/AACF screening agreement that addresses material transfer, intellectual property, and confidentiality issues. This agreement is discussed and is available earlier in this webpage.

After the agreement is in place, the submitter will provide the following information:

Name
Institution
Address
Telephone
FAX
Email
Product name
Manufacturer/developer
Chemical structure and molecular weight
If provided as a formulation, provide active ingredient structure and mwt information.
Availability of the compound in gram quantities. (If not, NIAID and AACF may be able to provide synthesis services.)
List of assays of interest to you. (Select from the list given above.)
Explanation of how data from the AACF Antiviral Testing in Animals resource will help you with the development of your product.
Biological data that supports your request (e.g., in vitro data, MOA, toxicity data, and Efficacy data, etc. Brief summaries of this information. Also references.)

AACF Antiviral Testing in Animals Program Clearinghouse

All materials for submission to the NIAID Antiviral Testing in Animals Program must be sent through the AACF Compound Screening Program Contractor, SRI. All compounds except immunomodulators should have supporting in vitro data before they can be considered as candidates for the AACF Antiviral Testing in Animals Program. (Immunomodulators may be accepted directly, but only on a case by case basis.) If no in vitro data is available, the compound should be screened first in the AACF in vitro Antiviral Testing Program.

Compound submitters will send SRI their compounds that have been accepted as screening candidates for the AACF Antiviral Testing in Animals Program. SRI will then catalog the materials, ship them to the appropriate laboratory for antiviral testing, receive the testing data from the testing laboratory, prepare a report for this data, and will send the data report to the submitter. During this process, inquiries regarding the status of submitted compounds and questions regarding the program and assays should be directed to SRI.